Virus News and Research

Latest Virus News and Research

Barriers, misinformation still prevent many from seeking flu protection for their families: Canadian Flu Report

According to the Canadian Flu Report released today, 40 per cent of parents are now more interested in vaccinating themselves and their children against seasonal flu following last year's H1N1 outbreak. Yet, significant barriers and misinformation are still preventing many from actually seeking proper flu protection for their families.

2 Jun 2010

Research findings advance the effort to develop AIDS vaccine

In findings that contribute to efforts to design an AIDS vaccine, a team led by Scripps Research Institute scientists has determined the structure of an immune system antibody molecule that effectively acts against most strains of human immunodeficiency virus, the virus that causes AIDS.

2 Jun 2010

ZymoGenetics commences Phase 2B study of PEG-Interferon lambda in hepatitis C

ZymoGenetics, Inc. today announced the initiation of the second part of a Phase 2 clinical trial with PEG-Interferon lambda (IL-29) and ribavirin in treatment-naïve patients with chronic hepatitis C virus (HCV) infection. ZymoGenetics is developing the investigational compound PEG-Interferon lambda in collaboration with Bristol-Myers Squibb Company.

2 Jun 2010

AFFiRiS to explore ProBioGen's HuALN technology for AFFITOME-based vaccination concept

AFFiRiS AG will explore ProBioGen's proprietary Human Artificial Lymph Node Technology (HuALN) as analytical tool for its AFFITOME®-based vaccination concept. Under the contract with ProBioGen, AFFiRiS will evaluate the HuALN technology as a human organoid model to investigate drug-related effects in the context of the human immune system in order to select vaccine candidates best suited to be applied in humans.

2 Jun 2010

Alnylam, Mount Sinai scientists discover svRNAs that play a critical role in influenza A virus replication

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the publication of new research findings in the journal Proceedings of the National Academy of Sciences (PNAS) by Alnylam scientists and collaborators from Mount Sinai School of Medicine. In the new study, Alnylam and Mount Sinai scientists discovered a novel class of virus-produced small non-coding RNAs, called small viral RNAs (svRNAs), which play a critical role in the replication of influenza A virus.

2 Jun 2010

Anti-Dengue drug candidates demonstrate efficacy in preliminary cell culture studies

NanoViricides, Inc. reports that its anti-Dengue drug candidates demonstrated significant efficacy in the recently completed preliminary cell culture studies. The studies were performed in the laboratory of Dr. Eva Harris, Professor of Infectious Diseases at the University of California, Berkeley.

2 Jun 2010

New report shows one in three young women receive HPV vaccine to prevent cervical cancer

Only about one in three young women has received the human papillomavirus vaccine to help prevent cervical cancer, according to a new report from researchers at Washington University School of Medicine in St. Louis.

2 Jun 2010

New technique transforms iPS cells into natural tumor killers

A technique for producing natural killer T (NKT) cells, known for their role in suppressing tumor growth, has been successfully demonstrated for the first time using induced pluripotent stem (iPS) cells. Developed by researchers at RIKEN, Japan’s flagship research institution, the technique opens the door to effective new cell-targeted treatments for cancer.

1 Jun 2010

AAPA recognizes role of PAs in transforming health care delivery with 2010 PAragon Awards

The American Academy of Physician Assistants celebrated the role of physician assistants in transforming health care delivery at its 38th Annual Physician Assistant Conference in Atlanta yesterday with its presentation of the 2010 PAragon Awards.

1 Jun 2010

Hepatitis C investigations intensify as number of women infected by doctor rises

In recent news 12 women had been infected with the Hepatitis C virus allegedly from an anaesthetist Dr James Latham Peters, practising at an abortion clinic, Croydon Day Surgery. As the investigations continue the number of infected women has risen to 44.

1 Jun 2010

Celladon announces 6-month data from Phase 2 clinical trial of MYDICAR in advanced heart failure patients

Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, today announced that six-month data from its Phase 2 clinical trial of MYDICAR® show improvements in clinical outcomes and disease markers in advanced heart failure patients treated with the genetically targeted enzyme replacement therapy.

31 May 2010

Targeted Genetics's partner Celladon presents Phase II trial data with MYDICAR at Heart Failure Congress 2010

Targeted Genetics Corporation announced that its partner, Celladon Corporation, presented full data today that show the first Phase II trial with MYDICAR® for the treatment of advanced heart failure has met its primary safety and efficacy endpoints, as prospectively defined in the Phase II trial protocol.

31 May 2010

RNA viruses hijack cellular enzyme to create viral replication factories on cell membranes

Nihal Altan-Bonnet, assistant professor of cell biology, Rutgers University in Newark, and her research team have made a significant new discovery about RNA viruses and how they replicate themselves.

29 May 2010

RNAi therapy shuts down gene critical to RSV, prevents virus replication

John DeVincenzo, MD, professor and researcher in the Departments of Pediatrics and Molecular Sciences at the University of Tennessee Health Science Center (UTHSC), has proven for the first time that a totally new concept in drug design can be used to treat human disease. Dr. DeVincenzo, who also serves as a children's infectious diseases specialist at Le Bonheur Children's Hospital, conducted his study at the Children's Foundation Research Center, a UT Health Science Center partner located at Le Bonheur.

29 May 2010

Study demonstrates protection against Ebola infection in nonhuman primates using RNAi

Scientists using tiny particles of genetic material to interfere in the replication process of the deadly Ebola virus have successfully prevented monkeys exposed to that virus from dying of hemorrhagic fever. The proof-of-concept study, published in this week's issue of The Lancet, suggests that such protection also should be possible in humans.

29 May 2010

HSV-1 may cause cognitive deficits: Study

Exposure to the common virus that causes cold sores may be partially responsible for shrinking regions of the brain and the loss of concentration skills, memory, coordinated movement and dexterity widely seen in patients with schizophrenia, according to research led by Johns Hopkins scientists.

29 May 2010

Allergic reactions prevent people with allergic asthma from generating healthy immune response to influenza

New research from UT Southwestern Medical Center suggests that allergic reactions to pet dander, dust mites and mold may prevent people with allergic asthma from generating a healthy immune response to respiratory viruses such as influenza.

29 May 2010

Globe and Mail examines links between maternal health, HIV/AIDS ahead of G8 summit

"While the G8 is putting maternal health at the top of its agenda for next month's summit, fears are growing that the club of wealthy nations is neglecting one of the biggest killers of women: AIDS," the Globe and Mail reports in a piece that examines the impact of HIV/AIDS on women and what the newspaper describes as the G8's "backtracking" on previous pledges to provide universal access HIV/AIDS drugs.

29 May 2010

Advaxis doses first patient in FDA-approved phase II CIN trial

Advaxis, Inc., the live, attenuated Listeria monocytogenes biotechnology company, has dosed the first patient in its US Food and Drug Administration -approved, phase II clinical trial in cervical intraepithelial neoplasia, commonly known as cervical dysplasia.

28 May 2010

Effective infant vaccination against pneumonia needed in sub-Saharan Africa

Researchers at the University of Warwick, and the Kenya Medical Research Institute, Kilifi, Kenya, have found that respiratory syncytial virus (RSV) appears to be the predominant virus detected among infants and children hospitalized in Kenya with severe pneumonia, according to a study in the May 26 issue of JAMA. The contribution to this severe disease by an individual pathogen stresses the need for effective infant vaccination.

28 May 2010

Virus News and Research

Latest Virus News and Research

Barriers, misinformation still prevent many from seeking flu protection for their families: Canadian Flu Report

Research findings advance the effort to develop AIDS vaccine

ZymoGenetics commences Phase 2B study of PEG-Interferon lambda in hepatitis C

AFFiRiS to explore ProBioGen's HuALN technology for AFFITOME-based vaccination concept

Alnylam, Mount Sinai scientists discover svRNAs that play a critical role in influenza A virus replication

Anti-Dengue drug candidates demonstrate efficacy in preliminary cell culture studies

New report shows one in three young women receive HPV vaccine to prevent cervical cancer

New technique transforms iPS cells into natural tumor killers

AAPA recognizes role of PAs in transforming health care delivery with 2010 PAragon Awards

Hepatitis C investigations intensify as number of women infected by doctor rises

Celladon announces 6-month data from Phase 2 clinical trial of MYDICAR in advanced heart failure patients

Targeted Genetics's partner Celladon presents Phase II trial data with MYDICAR at Heart Failure Congress 2010

RNA viruses hijack cellular enzyme to create viral replication factories on cell membranes

RNAi therapy shuts down gene critical to RSV, prevents virus replication

Study demonstrates protection against Ebola infection in nonhuman primates using RNAi

HSV-1 may cause cognitive deficits: Study

Allergic reactions prevent people with allergic asthma from generating healthy immune response to influenza

Globe and Mail examines links between maternal health, HIV/AIDS ahead of G8 summit

Advaxis doses first patient in FDA-approved phase II CIN trial

Effective infant vaccination against pneumonia needed in sub-Saharan Africa

A new way of characterising biomolecules eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Virus News and Research

Latest Virus News and Research

A new way of characterising biomolecules eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Newsletters you may be interested in